Association betweenMRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease

Journal of Hypertension

Volumn 35, Issue 4, 2017, Pages 737-744

  Lorbeer, Roberto ^a,f   Bayerl, Christian ^a   Auweter, Sigrid ^a   Rospleszcz, Susanne ^b   Lieb, Wolfgang ^c   Meisinger, Christa ^b,d   Heier, Margit ^b,d   Peters, Annette ^b,e,f   Bamberg, Fabian ^a,g   Hetterich, Holger ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d KLINIKUM AUGSBURG   (Germany)

^e GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Blood Pressure; Hepatic Fat Fraction; Hypertension; MRI; Population

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FAT CONTENT; FATTY LIVER; FEMALE; HEPATIC FAT FRACTION; HEPATIC PORTAL VEIN; HUMAN; HYPERTENSION; IMAGE ANALYSIS; LEFT LIVER LOBE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RIGHT LIVER LOBE; SYSTOLIC BLOOD PRESSURE; COMPLICATION; DIAGNOSTIC IMAGING; LIVER; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; BLOOD PRESSURE; FATTY LIVER; FEMALE; HUMANS; HYPERTENSION; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 85030757454     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001245     Document Type: Article

References (39)

1. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9:126-133.
2. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230:258-267.
3. Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol 2015; 27:193-199.
4. Mellinger JL, Pencina KM, Massaro JM, Hoffmann U, Seshadri S, Fox CS, et al. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. J Hepatol 2015; 63:470-476.
5. Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens 2015; 33:1207-1214.
6. Patel S, Lawlor DA, Ferreira DL, Hughes AD, Chaturvedi N, Callaway M, et al. The association of nonalcoholic fatty liver disease with central and peripheral blood pressure in adolescence: findings from a crosssectional study. J Hypertens 2015; 33:546-553.
7. Ducluzeau PH, Boursier J, Bertrais S, Dubois S, Gauthier A, Rohmer V, et al. MRI measurement of liver fat content predicts the metabolic syndrome. Diabetes Metab 2013; 39:314-321.
8. Vasunta RL, Kesaniemi YA, Ylitalo AS, Ukkola OH. High ambulatory blood pressure values associated with nonalcoholic fatty liver in middle-Aged adults. J Hypertens 2012; 30:2015-2019.
9. Zhang T, Zhang C, Zhang Y, Tang F, Li H, Zhang Q, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: A prospective cohort study. Atherosclerosis 2015; 240:144-148.
10. Qayyum A, Chen DM, Breiman RS, Westphalen AC, Yeh BM, Jones KD, et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? Clin Imaging 2009; 33:110-115.
11. De Larochelliere E, Cote J, Gilbert G, Bibeau K, Ross MK, Dion-Roy V, et al. Visceral/epicardial adiposity in nonobese and apparently healthy young adults: Association with the cardiometabolic profile. Atherosclerosis 2014; 234:23-29.
12. Koch M, Borggrefe J, Schlesinger S, Barbaresko J, Groth G, Jacobs G, et al. Association of a lifestyle index with MRI-determined liver fat content in a general population study. J Epidemiol Community Health 2015; 69:732-737.
13. Pozzato C, Radaelli G, Dall'Asta C, Verduci E, Villa A, Villa C, et al. MRI in identifying hepatic steatosis in obese children and relation to ultrasonography and metabolic findings. J Pediatr Gastroenterol Nutr 2008; 47:493-499.
14. Rathmann W, Strassburger K, Heier M, Holle R, Thorand B, Giani G, Meisinger C. Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 2009; 26:1212-1219.
15. Bamberg F, Hetterich H, Rospleszcz S, Lorbeer R, Auweter SD, Schlett CL, et al. Subclinical disease in subjects with prediabetes, diabetes and normal controls from the general population: The KORA MRI-study. Diabetes 2016; Epub ahead of print. doi:10.2337/db16-0630.
16. Hetterich H, Bayerl C, Peters A, Heier M, Linkohr B, Meisinger C, et al. Feasibility of a three-step magnetic resonance imaging approach for the assessment of hepatic steatosis in an asymptomatic study population. Eur Radiol 2016; 26:1895-1904.
17. Zhong X, Nickel MD, Kannengiesser SA, Dale BM, Kiefer B, Bashir MR. Liver fat quantification using a multistep adaptive fitting approach with multiecho GRE imaging. Magn Reson Med 2014; 72:1353-1365.
18. Pineda N, Sharma P, Xu Q, Hu X, Vos M, Martin DR. Measurement of hepatic lipid: high-speed T2-corrected multiecho acquisition at 1H MR spectroscopy-A rapid and accurate technique. Radiology 2009; 252:568-576.
19. Meisinger C, Heier M, Volzke H, Lowel H, Mitusch R, Hense HW, Ludemann J. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006; 24:293-299.
20. Whitworth JA, World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
21. Deutschen Liga zur Bekämpfung des hohen Blutdruckes e.V. Empfehlungen zur Hochdruckbehandlung in der Praxis und zur Therapie hypertensiver Notfälle. Heidelberg: Deutschen Liga zur Bekämpfung des hohen Blutdruckes e.V.; 2010.
22. Collaboration NCDRF. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: A pooled analysis of 96 population-based studies with 331, 288 participants. Lancet Diab Endocrinol 2015; 3:624-637.
23. Seissler J, Feghelm N, Then C, Meisinger C, Herder C, Koenig W, et al. Vasoregulatory peptides pro-endothelin-1 and pro-Adrenomedullin are associated with metabolic syndrome in the population-based KORA F4 study. Eur J Endocrinol 2012; 167:847-853.
24. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: Antihypertensive therapy and systolic blood pressure. Stat Med 2005; 24:2911-2935.
25. Orsini N, Greenland S. A procedure to tabulate and plot results after flexible modeling of a quantitative covariate. Stata Journal 2011; 11:1-29.
26. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010; 29:1037-1057.
27. How can I explain a continuous by continuous interaction?: UCLA: Statistical Consulting Group. Available from: http://www.ats.ucla.edu/stat/mult-pkg/faq/general/citingats.htm [Accessed 15 September 2015].
28. Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens 2010; 28:1829-1835.
29. Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between nonalcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol 2014; 29:1926-1931.
30. Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, et al. The association between fatty liver disease and blood pressure in a population-based cohort study. J Hypertens 2012; 30:1260-1261.
31. Kotronen A, Laaksonen MA, Heliovaara M, Reunanen A, Tuomilehto J, Yki-Jarvinen H, et al. Fatty liver score and 15-year incidence of type 2 diabetes. Hepatol Int 2013; 7:610-621.
32. Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008; 29:939-960.
33. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Nonalcoholic fatty liver disease: A new and important cardiovascular risk factor? Eur Heart J 2012; 33:1190-1200.
34. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280:E745-E751.
35. Wu CH, Ho MC, Jeng YM, Hsu CY, Liang PC, Hu RH, et al. Quantification of hepatic steatosis: A comparison of the accuracy among multiple magnetic resonance techniques. J Gastroenterol Hepatol 2014; 29:807-813.
36. Volzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and nonalcoholic origin? World J Gastroenterol 2012; 18:3492-3501.
37. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: A meta-Analysis. Eur Radiol 2011; 21:87-97.
38. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Noninvasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51:433-445.
39. Runge JH, Bakker PJ, Gaemers IC, Verheij J, Hakvoort TB, Ottenhoff R, et al. Measuring liver triglyceride content in mice: noninvasive magnetic resonance methods as an alternative to histopathology. MAGMA 2014; 27:317-327.